CovidChloroV1, Main, Corpus, bibRecord, 001817

Cutaneous sıde-effects of the potential COVID-19 drugs.

Identifieur interne : 001817 ( Main/Corpus ); précédent : 001816; suivant : 001818

Cutaneous sıde-effects of the potential COVID-19 drugs.

Auteurs : Ümit Türsen ; Belma Türsen ; Torello Lotti

Source :

Dermatologic therapy [ 1529-8019 ] ; 2020.

RBID : pubmed:32358890

English descriptors

KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug-Related Side Effects and Adverse Reactions (epidemiology), Global Health (MeSH), Humans (MeSH), Incidence (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH), Skin Diseases (chemically induced), Skin Diseases (epidemiology).
MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- chemically induced : Skin Diseases.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Drug-Related Side Effects and Adverse Reactions, Pneumonia, Viral, Skin Diseases.
- Betacoronavirus, COVID-19, Global Health, Humans, Incidence, Pandemics, SARS-CoV-2.

Abstract

COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.

DOI: 10.1111/dth.13476
PubMed: 32358890
PubMed Central: PMC7262017

Links to Exploration step

pubmed:32358890

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cutaneous sıde-effects of the potential COVID-19 drugs.</title>
<author><name sortKey="Tursen, Umit" sort="Tursen, Umit" uniqKey="Tursen U" first="Ümit" last="Türsen">Ümit Türsen</name>
<affiliation><nlm:affiliation>Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tursen, Belma" sort="Tursen, Belma" uniqKey="Tursen B" first="Belma" last="Türsen">Belma Türsen</name>
<affiliation><nlm:affiliation>Department of Health Science, Toros University, Mersin, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name>
<affiliation><nlm:affiliation>Department of Dermatology, School of Medicine, Marconi University, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32358890</idno>
<idno type="pmid">32358890</idno>
<idno type="doi">10.1111/dth.13476</idno>
<idno type="pmc">PMC7262017</idno>
<idno type="wicri:Area/Main/Corpus">001817</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001817</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cutaneous sıde-effects of the potential COVID-19 drugs.</title>
<author><name sortKey="Tursen, Umit" sort="Tursen, Umit" uniqKey="Tursen U" first="Ümit" last="Türsen">Ümit Türsen</name>
<affiliation><nlm:affiliation>Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tursen, Belma" sort="Tursen, Belma" uniqKey="Tursen B" first="Belma" last="Türsen">Belma Türsen</name>
<affiliation><nlm:affiliation>Department of Health Science, Toros University, Mersin, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name>
<affiliation><nlm:affiliation>Department of Dermatology, School of Medicine, Marconi University, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Dermatologic therapy</title>
<idno type="eISSN">1529-8019</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Global Health (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Skin Diseases (chemically induced)</term>
<term>Skin Diseases (epidemiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Skin Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Pneumonia, Viral</term>
<term>Skin Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Global Health</term>
<term>Humans</term>
<term>Incidence</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32358890</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-8019</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Dermatologic therapy</Title>
<ISOAbbreviation>Dermatol Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Cutaneous sıde-effects of the potential COVID-19 drugs.</ArticleTitle>
<Pagination><MedlinePgn>e13476</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/dth.13476</ELocationID>
<Abstract><AbstractText>COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.</AbstractText>
<CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Türsen</LastName>
<ForeName>Ümit</ForeName>
<Initials>Ü</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-5807-6759</Identifier>
<AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Türsen</LastName>
<ForeName>Belma</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-4735-0705</Identifier>
<AffiliationInfo><Affiliation>Department of Health Science, Toros University, Mersin, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lotti</LastName>
<ForeName>Torello</ForeName>
<Initials>T</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-0840-1936</Identifier>
<AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, Marconi University, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Dermatol Ther</MedlineTA>
<NlmUniqueID>9700070</NlmUniqueID>
<ISSNLinking>1396-0296</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">dermatology</Keyword>
<Keyword MajorTopicYN="N">side-effects</Keyword>
<Keyword MajorTopicYN="N">skin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32358890</ArticleId>
<ArticleId IdType="doi">10.1111/dth.13476</ArticleId>
<ArticleId IdType="pmc">PMC7262017</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Australas J Dermatol. 2018 Aug;59(3):e168-e174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29411351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dermatol Ther. 2020 Jul;33(4):e13476</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32358890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Immunol. 2014;121:191-211</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24388216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32215952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2015 Apr 28;(4):CD003262</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25919144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jun 15;251:117627</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 Apr 10;21(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32290293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mediterr J Rheumatol. 2019 Sep 30;30(3):177-185</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32185362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Ann. 2020 Mar 1;49(3):e132-e139</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32155279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cancer. 2016 Jun;60:12-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27043866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2018 Sep 06;9:CD001127</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30187450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cutan Pathol. 2006 Apr;33(4):309-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16630182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Cent Sci. 2020 Mar 25;6(3):315-331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32226821</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medicine (Baltimore). 2019 May;98(19):e15553</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31083216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cutan Ocul Toxicol. 2017 Jun;36(2):199-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27345420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2012;6(6):e1685</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22679525</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Dermatol. 2019 Nov 27;11(3):317-321</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31911769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Dermatol Venereol. 2016 May;143(5):336-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27161648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105967</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32259575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Med Res. 2018 Jun;16(1-2):41-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29610119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2016 Aug;55(8):1499-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27143789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian Dermatol Online J. 2019 Aug 28;10(5):503-518</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31544068</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2020 Jan;25(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32019669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2002 Dec;46(12):3392-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12483751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Dermatol. 2001 Jul;40(7):427-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11678994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ecancermedicalscience. 2020 Mar 27;14:1022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32256705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pharmacol. 2016 Jan-Feb;48(1):83-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26997729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 Mar 25;21(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32218340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dermatol Ther. 2018 Sep;31(5):e12679</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30230152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2010 Oct;63(4):549-61; quiz 561-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20846563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):234-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18583790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mil Med Res. 2020 Feb 6;7(1):4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32029004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2016 Feb;44(2):275-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26584195</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e250-e251</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32294264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ Case Rep. 2011 Aug 04;2011:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22687684</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9-vi22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31769856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2016 Sep 15;194(6):701-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27014936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Drugs Dermatol. 2017 Jul 1;16(7):714-716</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28697228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Case Rep Intern Med. 2019 Dec 19;7(1):001383</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chemother. 2017 Dec;29(6):380-382</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27741937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 1996 Sep;47(3):674-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8797463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Dermatol. 2014 May 17;6(2):145-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24932169</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001817 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001817 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32358890
   |texte=   Cutaneous sıde-effects of the potential COVID-19 drugs.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32358890" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Cutaneous sıde-effects of the potential COVID-19 drugs.

Cutaneous sıde-effects of the potential COVID-19 drugs.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki